Currently available biologic therapies (biologics) for asthma

Anti-IgE therapy

- Omalizumab (Xolair). Adult dose: 150–375 mg SC every 2–4 weeks (based on patient’s weight and pre-treatment serum IgE level). Pediatric dose: Not indicated for children younger than 6 years. 75–375 mg SC every 2–4 weeks (based on patient’s weight and pre-treatment serum IgE level)

Anti-IL5 therapy

- Mepolizumab (Nucala), 100 mg SC every 4 weeks. Not indicated for children younger than 18 years.

- Benralizumab (Fasenra), 30 mg SC every 4 weeks for the first 3 doses, then every 8 weeks thereafter. Not indicated for children younger than 18 years.

- Reslizumab (Cinqair), 3 mg/kg IV every 4 weeks. Not indicated for children younger than 18 years.

References:

Asthma, Practical guide for allergy and immunology in Canada 2018 https://buff.ly/2CXsbwf